The global sickle cell disease treatment market size was estimated to be USD 2.70 billion in 2023 and is expected to reach at USD 20.32 billion by 2034 with a CAGR of 20.14% during the forecast period 2024-2034. Rise in the occurrence of sickle cell disease (SCD), increasing support from government initiatives, surge in awareness among the population, severity associated with the disorder is increasing, prompting efforts from government & non-government bodies to enhance public awareness of the disease & its seriousness, increasing approval of novel therapeutic drugs for treating the disease, government bodies are actively engaged in improving healthcare services, and growing introduction of therapeutic drugs for sickle cell disease are some of the key factors boosting the market growth.
Growing introduction of therapeutic drugs for sickle cell disease is predicted to boost the market growth during the forecast period. Sickle cell disease (SCD) is a hereditary blood disorder characterized by abnormal, rigid, sickle-shaped red blood cells (RBCs), caused due to mutations in the beta-globin gene. Individual differences exist regarding the disease's severity. Hence, market players are focusing on development of novel medications for sickle cell disease. For instance, in April 2022, Real-world data on Endari, the company's prescription-grade L-glutamine oral powder, have been made public by Emmaus Life Sciences, Inc. The data focuses on the prevention of acute complications from sickle cell disease (SCD) and hemolysis in pediatric and adult patients in French Guiana and Qatar.
By treatment, blood transfusion was the highest revenue-grossing segment in the global sickle cell disease treatment market in 2023 owing to the widespread adoption, scarcity of alternative treatment choices, rise in blood donations, the efficacy of blood transfusion methods, and the increasing approvals from regulatory authorities. For instance, in April 2023, The U.S. FDA has awarded Orphan Drug Designation to Editas Medicine, Inc. for its EDIT-301, designed for treating sickle cell disease. Additionally, pharmacotherapy is predicted to grow at fastest CAGR during the forecast period owing to the rising rate of prescription for pharmaceutical drugs and the surge in the introduction of novel therapeutic medications for treating the disease are notable trends.
By end-user, hospital was the highest revenue-grossing segment in the global sickle cell disease treatment market in 2023. Hospitals serve as the main hubs for diagnosing and treating the disease. The significant share in this segment is attributed to the presence of superior healthcare services, a substantial patient pool, and enhanced healthcare infrastructure. Additionally, the majority of blood transfusions and bone marrow transplants take place in hospital facilities, further contributing to the segment's high share. Additionally, specialty clinics is predicted to grow at fastest CAGR during the forecast period owing to the convenience of consultation, the enhancement of clinic facilities, growing adoption of therapeutic drugs for managing sickle cell disease, and the increasing approval of new drugs. For instance, in July 2022, Oxbryta from Global Blood Therapeutics, Inc. has been granted market approval by the Medicines and Healthcare Products Regulatory Agency for use in Great Britain.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of diseases, a surge in healthcare infrastructure, efforts by government & non-government bodies to raise awareness, growing research and development activities, and a rise in regulatory approvals .For instance, in May 2022, Graphite Bio, Inc. has revealed that the U.S. Food and Drug Administration (FDA) has bestowed Fast Track Designation upon GPH101 for the treatment of sickle cell disease (SCD). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising approval of novel drugs for treating sickle cell disease, growing awareness about the disease among the public, surge in adoption of technologically advanced therapeutic options, upsurge in government initiatives aimed at managing the disease burden and increasing mergers & acquisitions within market players. For instance, in October 2022, Pfizer Inc. has successfully finalized the acquisition of Global Blood Therapeutics, Inc., a company specializing in the development and commercialization of drugs for the treatment of sickle cell disease (SCD).
Growing introduction of therapeutic drugs for sickle cell disease is predicted to boost the market growth during the forecast period. Sickle cell disease (SCD) is a hereditary blood disorder characterized by abnormal, rigid, sickle-shaped red blood cells (RBCs), caused due to mutations in the beta-globin gene. Individual differences exist regarding the disease's severity. Hence, market players are focusing on development of novel medications for sickle cell disease. For instance, in April 2022, Real-world data on Endari, the company's prescription-grade L-glutamine oral powder, have been made public by Emmaus Life Sciences, Inc. The data focuses on the prevention of acute complications from sickle cell disease (SCD) and hemolysis in pediatric and adult patients in French Guiana and Qatar.
By treatment, blood transfusion was the highest revenue-grossing segment in the global sickle cell disease treatment market in 2023 owing to the widespread adoption, scarcity of alternative treatment choices, rise in blood donations, the efficacy of blood transfusion methods, and the increasing approvals from regulatory authorities. For instance, in April 2023, The U.S. FDA has awarded Orphan Drug Designation to Editas Medicine, Inc. for its EDIT-301, designed for treating sickle cell disease. Additionally, pharmacotherapy is predicted to grow at fastest CAGR during the forecast period owing to the rising rate of prescription for pharmaceutical drugs and the surge in the introduction of novel therapeutic medications for treating the disease are notable trends.
By end-user, hospital was the highest revenue-grossing segment in the global sickle cell disease treatment market in 2023. Hospitals serve as the main hubs for diagnosing and treating the disease. The significant share in this segment is attributed to the presence of superior healthcare services, a substantial patient pool, and enhanced healthcare infrastructure. Additionally, the majority of blood transfusions and bone marrow transplants take place in hospital facilities, further contributing to the segment's high share. Additionally, specialty clinics is predicted to grow at fastest CAGR during the forecast period owing to the convenience of consultation, the enhancement of clinic facilities, growing adoption of therapeutic drugs for managing sickle cell disease, and the increasing approval of new drugs. For instance, in July 2022, Oxbryta from Global Blood Therapeutics, Inc. has been granted market approval by the Medicines and Healthcare Products Regulatory Agency for use in Great Britain.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of diseases, a surge in healthcare infrastructure, efforts by government & non-government bodies to raise awareness, growing research and development activities, and a rise in regulatory approvals .For instance, in May 2022, Graphite Bio, Inc. has revealed that the U.S. Food and Drug Administration (FDA) has bestowed Fast Track Designation upon GPH101 for the treatment of sickle cell disease (SCD). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising approval of novel drugs for treating sickle cell disease, growing awareness about the disease among the public, surge in adoption of technologically advanced therapeutic options, upsurge in government initiatives aimed at managing the disease burden and increasing mergers & acquisitions within market players. For instance, in October 2022, Pfizer Inc. has successfully finalized the acquisition of Global Blood Therapeutics, Inc., a company specializing in the development and commercialization of drugs for the treatment of sickle cell disease (SCD).
Segmentation: Sickle Cell Disease Treatment Market Report 2023 - 2034
Sickle Cell Disease Treatment Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Pharmacotherapy
- Blood Transfusion
- Bone Marrow Transplant
Sickle Cell Disease Treatment Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Clinics
- Others
Sickle Cell Disease Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Sickle Cell Disease Treatment Market: Treatment Estimates & Trend Analysis
8. Sickle Cell Disease Treatment Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Sickle Cell Disease Treatment Market
11. Europe Global Sickle Cell Disease Treatment Market
12. Asia Pacific Global Sickle Cell Disease Treatment Market
13. Latin America Global Sickle Cell Disease Treatment Market
14. MEA Global Sickle Cell Disease Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- GlycoMimetics
- Novartis AG
- CRISPR Therapeutics
- Pfizer Inc.
- Graphite Bio Inc.
- Bristol-Myers Squibb Company
- bluebird bio Inc.
- Emmaus Medical Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.7 Billion |
| Forecasted Market Value ( USD | $ 20.32 Billion |
| Compound Annual Growth Rate | 20.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
